Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2019)... ... March 28, 2019 , ... ... programme, a new PT programme entirely dedicated to Chinese biobanks was launched in ... Environmental Repositories (ISBER) and the Biobank Branch, China Medicinal Biotech Association (BBCMBA). The ...
(Date:3/29/2019)... ... March 29, 2019 , ... ... its new multi-product cell therapy facility. The new facility, which will anchor the ... new state of the art manufacturing capabilities to support clinical cell therapy trials. ...
(Date:3/26/2019)... ... March 26, 2019 , ... The American Society of ... the Society's 2019 Outstanding Achievement Award, Outstanding New Investigator Awards, and the Sonia ... ASGCT 22nd Annual Meeting . , Outstanding Achievement Award, Dr. John Rossi, ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... , ... March 19, 2019 , ... ... learning cloud solutions, today announced it has begun offering NVIDIA® DGX-1™ deep learning ... can utilize DGX-1, designed to provide the highest performance for artificial intelligence and ...
(Date:3/14/2019)... ... March 14, 2019 , ... EyeCRO LLC ... City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical Research ... the fifth institution in Oklahoma to receive this prestigious endorsement. The award ...
(Date:3/14/2019)... , ... March 14, 2019 , ... ... release announcing that its Canadian partner, the Eye Machine Canada Inc., had been ... Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD). , The previous month, ...
(Date:3/14/2019)... , ... March 14, 2019 ... ... of a preclinical gold standard solution for preclinical research organizations. It is ... with end-to-end workflows, connected systems and facilities, innovative technology-driven automated data capture ...
Breaking Biology Technology: